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Section A 
Short Answer Questions 
Total No of Marks for this Section:  100 
 
Answer all the questions in Section A 
This section should be answered in the Answer Booklet provided. 
 




Question 1. Drug industry 
Sketch the drug development pipeline assuming that it is a cycle. Include details of the expected 
timeframes, costs and number of compounds that reach each stage (as a proportion of drugs delivered 
to market).  
Explain what information is needed to pass each go/no-go checkpoint in the development pathway. 
(Marks: 10) 
 
Question 2. Drug development process 
(a) Illustrate, with examples, THREE potential sources/routes for lead compounds for drug 
discovery. 
(Marks: 3) 
(b) In drug development, explain TWO reasons for conducting Phase IV (post-marketing 
surveillance) studies after a new drug has been released on the market. 
(Marks: 2) 
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Question 3. Drug development for neglected tropical diseases  
Tropical diseases affect more than 1 billion people, mostly in developing regions of the world.  
(a) Give 2 examples of tropical diseases.  
(Marks: 2) 
(b) Give FOUR parameters for developing drugs targeting neglected tropical diseases (NTD) and 
compare/contrast the importance of those parameters in NTD drug development compared with 
development of drugs for diseases more common in developed countries. 
(Marks: 8) 
 
Question 4. Target binding 
(a) There are various ways that drugs modulate the action of receptors, channels and enzymes. 
Using diagrams explain the similarities and differences between: 
i. Competitive enzyme inhibition 
ii. Un-competitive inhibition 
iii. Allosteric modulation 
iv. Receptor agonism 
 (Marks: 8) 
(b) Rank the intermolecular forces in terms of strength. 
 (Marks: 2) 
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Question 5. Oncology agents 
 




(b) Side effects of anti-cancer agents are often due to “on pathway” effects. Explain the term “on 
pathway” and discuss the difference between on and off pathway effects.  
(Marks: 2) 
 
(c) Cyclophosphamide and fluorouracil (structure below) are common chemotherapeutic agents.  
 
          
 




ii. Which families (overall mode of action) of drugs do these come from? 
(Marks: 2) 
 




iv. Suggest structures for one analogue of each of cyclophosphamide and fluorouracil that 
exploit similar biological-chemistry but have different pathways into the cell. Explain your 
choices. 
(Marks: 2) 
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Question 6. Structure based drug design 
 
(a) In terms of medicinal chemistry and drug development, define: 
i. Pharmacophore 




(b) In the diagram below, what type of organic reaction mechanism is occurring?  
(Marks: 1) 
 
(c) Using the concept of bioisosteres: 
i. Design a reversible competitive inhibitor for the following reaction. Explain your reasoning. 
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Question 7. Ring based chemistry in drug design 
(a) Explain, with an example, why drugs that are analogues of natural regulators (small molecules or 
peptides) often contain more cyclic moieties than the regulators that they use as a starting point 
for their design. 
(Marks: 2) 
(b) Tricyclic moieties are common in drug molecule. However, the specific shape of the molecule 
can be manipulated by changing the atoms in the central ring. Describe how changes to the size, 
bonding and atoms in the central ring of the following compound (a xanthylium salt) would 
affect the overall three dimensional shape of the molecule. 
 
Factors to consider are: 
- Non-aromatic carbons 
- Change to a seven-membered ring 
- Introduction of different heteroatoms 
- Combination of heteroatoms and seven membered ring 
- Introduction of an alkene group in a seven-membered ring 
 (Marks: 8) 
 
Question 8. Instrumental assays 
(a) Explain the following terms: 
i. Metabolomics 
ii. Biophysical screening 
iii. Functional assay 
 (Marks 3) 
(b) Compare and contrast two instrumental methods for determining the binding of drugs to a 
membrane bound receptor. You should consider factors such as rate of assay throughput, and 
amount (and types) of information generated by a given technique. 
(Marks 7) 
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Question 9. Cell wall synthesis inhibitor antibiotics 
The following are all compounds used in the treatment of bacterial infections.  
Explain how the different structures of these compounds relate to their different roles and/or differing 
mechanisms of actions in treatment. Relevant areas will include antibiotic resistance, oral bioavailability 
and metabolic stability. 
 
Penicillin G   Amoxycillin   Methicillin 
 
 
Vancomycin           Clavulanic acid 
 (Marks: 10) 
Question 10.  
Give a detailed explanation of one or more areas of medicinal chemistry that HAVE NOT been covered in 
this exam.  
 (Marks: 10) 
 
 
